| Recruiting | N/A | 50000 | RoW | No additional intervention will be administered. | Peking Union Medical College Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Tianjin First Central Hospital, Hebei Medical University Third Hospital, Dalian Hospital of Chinese Traditional and Western Medicine, The Second Affiliated Hospital of Harbin Medical University, Peking University Third Hospital, Beijing Shijingshan Hospital, The Second Medical Center of The General Hospital of the People's Liberation Army, Huamei hospital, University of Chinese Academy of Sciences, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital, Ruijin Hospital, The First People's Hospital of Changzhou, Affiliated Hospital of Nantong University, Nantong First People's Hospital, Shanghai Changzheng Hospital, Wuhan Union Hospital, China, Central South University, Guangdong Provincial People's Hospital, Nanfang Hospital of Southern Medical University, Lunjiao Hospital of Shunde Foshan, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou Second Hospital, Second Affiliated Hospital of Guangzhou Medical University, Shenzhen Second People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Sichuan Provincial People's Hospital, West China Fourth Hospital, Sichuan Province Orthopedic Hospital, The Second Affiliated Hospital of Chongqing Medical University, Daping Hospital, Army Medical Center of PLA, Guizhou Provincial Orthopedics Hospital, First Affiliated Hospital Xi'an Jiaotong University, Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, The First Affiliated Hospital of Zhengzhou University | Osteoporosis, Osteoporotic Fractures | 12/24 | 12/24 | | |
NCT06196918: Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients |
|
|
| Recruiting | N/A | 320 | RoW | Rivaroxaban 10 MG, Jiangsu Zhongbang pharmaceutical CO., LTD; Serial numbers: H20203733, Placebo, Jiangsu Zhongbang pharmaceutical CO., LTD | Nanfang Hospital, Southern Medical University | Glioma, Malignant | 08/24 | 02/25 | | |
